Colinz Laboratories Ltd
₹ 69.2
-1.07%
30 Oct
- close price
About
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations[1]
Key Points
- Market Cap ₹ 17.4 Cr.
- Current Price ₹ 69.2
- High / Low ₹ 87.9 / 36.1
- Stock P/E 35.6
- Book Value ₹ 50.4
- Dividend Yield 0.00 %
- ROCE 7.20 %
- ROE 5.23 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -0.07% over past five years.
- Company has a low return on equity of 5.41% over last 3 years.
- Promoter holding has decreased over last 3 years: -15.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 6.14 | 5.97 | |
| 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.72 | 5.63 | |
| Operating Profit | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.42 | 0.34 |
| OPM % | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 6.84% | 5.70% |
| 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | 0.48 | 3.28 | |
| Interest | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 | 0.05 |
| Depreciation | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 | 0.16 | 0.14 |
| Profit before tax | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 | 0.69 | 3.43 |
| Tax % | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 20.97% | 24.64% | |
| 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | 0.51 | 2.78 | |
| EPS in Rs | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.83 | 1.95 | 1.98 | 2.02 | 11.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 19% |
| 3 Years: | 2% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 28% |
| 3 Years: | 20% |
| 1 Year: | 67% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.52 | 10.19 |
| 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.39 | 0.45 | |
| 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | 2.35 | 1.58 | |
| Total Liabilities | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 | 14.74 |
| 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | 1.54 | 0.43 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.11 | 1.26 |
| 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | 10.13 | 13.05 | |
| Total Assets | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 | 14.74 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | 0.58 | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | 0.40 | 1.03 | -1.45 | 2.54 | |
| 0.03 | 0.00 | -0.01 | -0.11 | -0.01 | -0.04 | -0.16 | -0.03 | 0.01 | 0.01 | -0.23 | 0.01 | |
| 0.45 | -0.73 | -0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | 0.11 | 0.23 | 0.24 | 0.43 | |
| Net Cash Flow | 0.57 | -0.16 | 0.02 | 0.24 | 0.12 | 0.60 | 2.07 | 0.52 | 0.52 | 1.27 | -1.45 | 2.98 |
| Free Cash Flow | 0.09 | 0.58 | 0.04 | 0.34 | 0.12 | 0.54 | 2.00 | 0.43 | 0.40 | 1.03 | -1.71 | 2.54 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 26% | 136% | 22% | 106% | 43% | 210% | 659% | 105% | 89% | 224% | -253% | 650% |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 | 49.93 |
| Inventory Days | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 | 148.55 |
| Days Payable | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 | 80.64 |
| Cash Conversion Cycle | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 | 117.84 |
| Working Capital Days | 110.24 | 100.04 | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 73.22 | -60.64 |
| ROCE % | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.62% | 7.20% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Additions to property, plant and equipment (capex) Rs. in Lacs |
|
|||||||
| Cost of materials consumed Rs. in Lacs |
||||||||
| Purchase of trading goods Rs. in Lacs |
||||||||
| Total tangible assets - gross block (PPE) Rs. in Lacs |
||||||||
| Number of permanent employees count |
||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Dear sir, Please find the attached News Paper Publication as required under Regulation 47(3) of SEBI(LODR), 2015. for the Quarter and Half year ended on …
-
Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
- Board approved unaudited Q2 and half-year FY2026 results on 29 Oct 2026; auditor issued unqualified review.
-
Board Meeting Outcome for Outcome Of The Board Meeting Under Regulation 30 And 33 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
- Board approved unaudited results for quarter and half-year ended 30 Sep 2026; net profit Rs 252.77 lakh.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015.
- Board meeting on 29 Oct 2026 to approve Q2 and half-year FY2026-27 unaudited results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Dear Sir, PFA, The Compliance Certificate issued by our RTA for Sep-26 under regulation 74(5). Kindly take the same on records . For Colinz Labs …
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1]
http://www.colinz.com/about.html
CLL is a manufacturer and exporter of pharmaceutical formulations for allopathic, ayurvedic, nutraceticals in dosage forms of tablets, capsules, ointments, creams, granules, liquid, orals, injectables, syrups, suppsitories, etc. It also has certain specialized products for Gynaecology, cardiology, gastroenterology, etc.